Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms, Plasma Cell 3Multiple Myeloma 3Leukemia 2Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

Idarubicin 2Cytarabine 2fludarabine phosphate 1Thiotepa 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Isotretinoin 1Interferon-alpha 1Idoxuridine 1Drug Therapy 1Bromodeoxyuridine 1Biological Therapy 1BI 6727 1Arsenic Trioxide 1Antilymphocyte Serum 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myelomonocytic, Acute × Arsenic Trioxide × Clear all
NCT01835288 2018-05-21

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Withdrawn
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡